Slowly then suddenly
12 August 2020

CureVac’s potential coronavirus remedy is coveted by the U.S. president. The German firm’s also a key player in biotech’s hottest unproven technology. And it hopes to float at just $2.7 bln, around 10% of the market value of rival Moderna. That’s plenty to ensure a warm welcome.